Alexander T Faje1, Ariel L Barkan. 1. Division of Metabolism, Endocrinology, and Diabetes, Department of Neurosurgery, University of Michigan Medical Center and Veterans Affairs Medical Center, Ann Arbor, Michigan 48016, USA.
Abstract
CONTEXT: Previous studies have shown that mean 24-h GH concentrations determine plasma IGF-I levels in patients with acromegaly. However, we have recently shown that continuous GH infusion, mimicking the interpulse GH levels, was significantly more effective than the pulsatile GH administration at increasing IGF-I concentrations. OBJECTIVE: The aim of the study was to ascertain relative roles of total GH output (24-h mean), GH pulses, and interpulse GH level in determining plasma IGF-I concentrations. DESIGN AND SETTING: We conducted a point-in-time observational inpatient study in the General Clinical Research Center at the University of Michigan. PATIENTS OR OTHER PARTICIPANTS: Eighteen patients with acromegaly and 19 healthy control subjects participated in the study. INTERVENTION(S): We performed frequent (every 10 or 20 min) blood sampling over 24 h. MAIN OUTCOME MEASURE(S): Before data collection, we hypothesized that interpulse nadir levels of GH would correlate with IGF-I levels in normal and acromegalic subjects. RESULTS: Mean and valley levels of GH correlated with serum IGF-I levels (r(2) = 0.44 and 0.48, respectively) in normal and acromegalic patients in a log-linear fashion. The strongest correlation, however, was observed between the log of nadir GH and IGF-I concentrations (r(2) = 0.77). GH pulse mass did not significantly correlate with IGF-I (r(2) = 0.001). CONCLUSIONS: Plasma IGF-I concentrations correlated with mean 24-h GH concentrations. This relationship is dependent exclusively on the basal GH levels. GH pulses do not determine plasma IGF-I concentrations.
CONTEXT: Previous studies have shown that mean 24-h GH concentrations determine plasma IGF-I levels in patients with acromegaly. However, we have recently shown that continuous GH infusion, mimicking the interpulse GH levels, was significantly more effective than the pulsatile GH administration at increasing IGF-I concentrations. OBJECTIVE: The aim of the study was to ascertain relative roles of total GH output (24-h mean), GH pulses, and interpulse GH level in determining plasma IGF-I concentrations. DESIGN AND SETTING: We conducted a point-in-time observational inpatient study in the General Clinical Research Center at the University of Michigan. PATIENTS OR OTHER PARTICIPANTS: Eighteen patients with acromegaly and 19 healthy control subjects participated in the study. INTERVENTION(S): We performed frequent (every 10 or 20 min) blood sampling over 24 h. MAIN OUTCOME MEASURE(S): Before data collection, we hypothesized that interpulse nadir levels of GH would correlate with IGF-I levels in normal and acromegalic subjects. RESULTS: Mean and valley levels of GH correlated with serum IGF-I levels (r(2) = 0.44 and 0.48, respectively) in normal and acromegalicpatients in a log-linear fashion. The strongest correlation, however, was observed between the log of nadir GH and IGF-I concentrations (r(2) = 0.77). GH pulse mass did not significantly correlate with IGF-I (r(2) = 0.001). CONCLUSIONS: Plasma IGF-I concentrations correlated with mean 24-h GH concentrations. This relationship is dependent exclusively on the basal GH levels. GH pulses do not determine plasma IGF-I concentrations.
Authors: Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Stephen M Shalet; Mary Lee Vance; Patricia A Stephens Journal: J Clin Endocrinol Metab Date: 2006-04-24 Impact factor: 5.958
Authors: P C Hindmarsh; E Dennison; S M Pincus; C Cooper; C H Fall; D R Matthews; P J Pringle; C G Brook Journal: J Clin Endocrinol Metab Date: 1999-08 Impact factor: 5.958
Authors: M L Hartman; J D Veldhuis; M L Vance; A C Faria; R W Furlanetto; M O Thorner Journal: J Clin Endocrinol Metab Date: 1990-05 Impact factor: 5.958
Authors: C A Jaffe; B Ocampo-Lim; W Guo; K Krueger; I Sugahara; R DeMott-Friberg; M Bermann; A L Barkan Journal: J Clin Invest Date: 1998-07-01 Impact factor: 14.808
Authors: Sowmya Surya; Jeffrey F Horowitz; Naila Goldenberg; Alla Sakharova; Matthew Harber; Andrea S Cornford; Kathy Symons; Ariel L Barkan Journal: J Clin Endocrinol Metab Date: 2009-05-26 Impact factor: 5.958
Authors: Johannes D Veldhuis; Ferdinand Roelfsema; Daniel M Keenan; Steven Pincus Journal: J Clin Endocrinol Metab Date: 2010-10-06 Impact factor: 5.958
Authors: Georgiana Dobri; Soamsiri Niwattisaiwong; James F Bena; Manjula Gupta; John Kirwan; Lawrence Kennedy; Amir H Hamrahian Journal: Endocrine Date: 2018-11-10 Impact factor: 3.633
Authors: Jessica A Brzana; Chris G Yedinak; Johnny B Delashaw; Hume S Gultelkin; David Cook; Maria Fleseriu Journal: Pituitary Date: 2012-12 Impact factor: 4.107
Authors: Takara L Stanley; Meghan N Feldpausch; Caitlin A Murphy; Steven K Grinspoon; Hideo Makimura Journal: Growth Horm IGF Res Date: 2013-11-15 Impact factor: 2.372